For the quarter ending 2026-03-31, RNTX has $26,288K in assets. $14,697K in debts. $4,445K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 4,445 | 3,215 | 4,048 | 5,722 |
| Prepaid expenses and other current assets | 1,008 | 1,111 | 1,126 | 880 |
| Total current assets | 5,453 | 4,326 | 5,174 | 6,602 |
| Property and equipment, net | - | 0 | 0 | 1 |
| Goodwill | 6,330 | 6,330 | 6,330 | 6,330 |
| Intangible assets | 13,500 | 13,500 | 42,200 | 42,200 |
| Other non-current assets | 1,005 | 2 | 2 | 2,346 |
| Total assets | 26,288 | 24,158 | 53,706 | 57,479 |
| Accounts payable | 6,263 | 3,976 | 4,123 | 6,028 |
| Accrued expenses and other current liabilities | 2,451 | 2,204 | 1,621 | 1,666 |
| Notes payable, net | 4,923 | - | - | - |
| Total current liabilities | 13,637 | 6,180 | 5,744 | 7,694 |
| Other long-term liability | - | 0 | 0 | 0 |
| Deferred tax liability | 1,060 | 1,060 | 1,772 | 1,772 |
| Total liabilities | 14,697 | 7,240 | 7,516 | 9,466 |
| Convertible preferred stock, 0.001 par value, 5,000,000 shares authorized at march 31, 2026 and at december 31, 2025 24,610 shares issued and 12,232 shares outstanding at march 31, 2026 and at december 31, 2025 | 45,005 | 45,005 | 45,005 | 45,005 |
| Common stock, 0.001 par value 100,000,000 shares authorized at march 31, 2026 and at december 31, 2025 28,039,032 shares and 27,550,222 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 114 | 113 | 111 | 109 |
| Common stock subscribed | - | - | - | 22 |
| Additional paid-in capital | 373,643 | 373,133 | 370,422 | 366,644 |
| Accumulated other comprehensive loss | -62 | -62 | -44 | -44 |
| Accumulated deficit | -407,109 | -401,271 | -369,304 | -363,723 |
| Total liabilities, convertible preferred stock and stockholders' equity | 26,288 | 24,158 | 53,706 | 57,479 |
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX)